Does health insurance cover GLP-1 drugs and peptides? What decides the answer.

Does health insurance cover GLP-1 drugs and peptides? It depends on the plan's drug list, called a formulary, and on the reason the drug is prescribed. FDA-approved GLP-1 medicines are covered by some plans and not others. Compounded products and "research" peptides are not FDA-approved drugs, and none of the sources below says a plan covers them.

Here is the argument of this piece. A question that sounds like yes or no, does my insurance cover it, is really three questions. Is the product an FDA-approved drug? Is it on your specific plan's drug list this plan year? And did the prescription meet whatever conditions that plan attaches to the drug? The answer to the first decides whether the other two even apply. Nothing below is a suggestion to use, avoid or source any medication or compound, and nothing here is insurance, legal or medical advice. It reports what federal agencies and KFF say in writing, each with a date, and it ends with questions that belong on a plan comparison.

Does health insurance cover GLP-1 drugs for weight loss?

Sometimes, and it varies by plan and by approved use. KFF's analysis of 2024 federal Marketplace plan data, published on 12 June 2024, found that Wegovy, a drug approved for weight loss, was covered by just 1% of Marketplace prescription drug plans, compared with 82% for Ozempic, which contains the same active ingredient, semaglutide, but is approved only for diabetes. Of the few Marketplace plans that covered a GLP-1 drug approved for obesity, all required prior authorization. Those numbers are two years old and plans change every year, so they show how coverage can differ, not what any plan does today. In my reading, the striking part is that the same molecule landed on very different lists depending on its approved use.

Public programs follow rules set higher up. KFF's brief of 11 May 2026 states that Medicare has been prohibited by law from covering medications used specifically for weight loss, and that federal law gives states the option whether to cover drugs used for weight loss under Medicaid. The same brief covers the CMS pilot arrangements for GLP-1s in Medicare and Medicaid, the BALANCE Model and the Medicare GLP-1 Bridge. Those details are still moving, so the KFF brief itself is the place to check them rather than this article.

The same ingredient, semaglutide, was covered by 82% of Marketplace plans under one approval and 1% under another.

What is a formulary, and why does it decide the answer?

HealthCare.gov's glossary defines a drug list as a list of prescription drugs covered by a prescription drug plan or another insurance plan offering prescription drug benefits, and notes that it is also called a formulary. Its guidance on prescription coverage tells people to visit the insurer's website to review the list of prescriptions the plan covers, and says drugs on the plan's formulary usually cost less. Every plan keeps its own list, which is why "my insurance" is not one answer but one answer per plan, per plan year. When someone asks whether a medication is covered, the formulary and the plan's own conditions for that drug are the documents that answer it.

A drug missing from the list is not always the end of the question. HealthCare.gov describes an exceptions process in which the doctor must confirm to the health plan, orally or in writing, that the drug is appropriate for the person's medical condition. That is a process between a prescriber and a plan, and the plan makes the decision. Ozemback does not advise anyone whether to request one. It is mentioned here because it explains why a "not on the list" answer and a "never covered" answer are different things, and the HealthCare.gov page describing it is linked in the sources.

Does insurance cover peptides, including compounded and research products?

Start with a definition problem. Semaglutide and tirzepatide are themselves peptides, and FDA-approved drugs that contain them fall under the plan drug-list rules described above. The products behind most searches for peptide coverage are different: compounded versions of drugs, and items sold as research chemicals. The FDA's page on unapproved GLP-1 drugs, dated 1 October 2026, states that compounded drugs are not FDA approved, which means the agency does not review compounded drugs for safety, effectiveness or quality before they are marketed. A formulary is a list of prescription drugs, so the first thing to establish about any product is which of those two worlds it belongs to.

On research-labeled products the same FDA page is blunt. It says the agency has warned companies that illegally sold unapproved drugs containing semaglutide, tirzepatide, retatrutide, survodutide or mazdutide that were falsely labeled for research purposes or not for human consumption, and that these products have been sold directly to consumers for human use. The sources used for this article do not say that a health plan covers a product in either category, and this article does not suggest that any plan does. Whether a particular plan reimburses anything beyond its listed drugs is a question only that plan's documents can answer.

Some clinicians do prescribe compounded products under the pharmacy compounding rules, which is why the coverage question is a fair one to ask. A prescription does not make a product an FDA-approved drug, and a prescription alone does not put a product on a plan's list. The legal mechanics are covered in Ozemback's piece on 503A and 503B compounding and in the compound-by-compound guide to what is approved, and the current status of each compound is in the peptide status tracker. None of these pages is a recommendation to use or obtain any product.

Can someone on an ICHRA pick a plan around their medication?

An individual coverage HRA, or ICHRA, is now called a CHOICE Arrangement on HealthCare.gov, which describes it as a way for employers to give employees tax-free reimbursements for qualified medical expenses, including premiums and out-of-pocket costs, without offering traditional group coverage. HealthCare.gov states that to use the funds, employees must have their own individual health insurance plan, like one from the Marketplace. CMS's page on health reimbursement arrangements, last updated 10 December 2025, says individual coverage HRAs can be used to reimburse premiums for individual health insurance chosen by the employee. The governing rule is 26 CFR 54.9802-4, adopted in the Federal Register on 20 June 2019 (84 FR 28888, document 2019-12571).

My inference, flagged as such: because the employee rather than the employer selects the individual plan, the employee can compare plan drug lists before choosing one. That is a feature of how the arrangement is built, not a guarantee that any plan lists any drug. Employers and employees who want to understand how the reimbursement works can start with InsureICHRA, which publishes explainers on ICHRA setup and reimbursement. The drug-list check described below still has to be done plan by plan.

What should you ask when reviewing a plan?

Whatever the medication, the same short list of questions applies, and each one can be answered from the plan's own documents or by the plan. They are questions for a plan comparison, not medical or treatment advice, and none of them presumes that any particular drug is right for anyone.

1. Is the medication on the plan's drug list for the current plan year, and in which cost tier?
2. Is it covered for the reason it was prescribed, or only for a different approved use?
3. Does the plan require prior authorization or any other condition before it pays?
4. If the drug is not listed, how does the plan's exceptions process work, and who submits the request?
5. Does the plan cover only FDA-approved drugs, or does it say anything about compounded products?
6. Which pharmacies can dispense it under the plan?

For comparing individual health plans side by side, Calma Insurance has a section on medical conditions that includes obesity and weight management, where it notes that GLP-1 coverage varies between plans and changes from year to year. The point of any comparison is the same: read the current plan's drug list rather than assuming last year's answer still holds.

So what is the short version?

Coverage is decided by three things in order: whether the product is an FDA-approved drug, whether it is on your plan's drug list for this year, and whether the prescription meets the plan's conditions. For approved GLP-1 drugs the answer differs by plan and by approved use. For compounded and research-labeled products, none of the sources here says a plan covers them, and the FDA says plainly that compounded drugs are not FDA approved. Reading the plan's drug list is the step that cannot be skipped.

Disclosure: Calma Insurance and InsureICHRA are published by the same publisher as Ozemback. The two links above are not endorsements of any product, and Ozemback does not recommend any plan.

Ozemback, October 2026

Sources

1. FDA, FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss, page dated 1 October 2026. www.fda.gov
2. KFF, Costly GLP-1 Drugs are Rarely Covered for Weight Loss by Marketplace Plans, 12 June 2024 (2024 federal plan data). www.kff.org
3. KFF, What to Know About the BALANCE Model for GLP-1s in Medicare and Medicaid and the Medicare GLP-1 Bridge, 11 May 2026. www.kff.org
4. HealthCare.gov, Glossary: Drug list (formulary). www.healthcare.gov
5. HealthCare.gov, Prescription medications (checking coverage and the exceptions process). www.healthcare.gov
6. HealthCare.gov, CHOICE Arrangements (formerly Individual Coverage HRAs, or ICHRAs). www.healthcare.gov
7. CMS, Health Reimbursement Arrangements, last updated 10 December 2025. www.cms.gov
8. 26 CFR 54.9802-4, integration of HRAs and other account-based group health plans with individual health insurance coverage and Medicare. www.law.cornell.edu
9. Federal Register, Health Reimbursement Arrangements and Other Account-Based Group Health Plans, 84 FR 28888, 20 June 2019 (document 2019-12571). www.federalregister.gov